top of page

Foamix’s FMX103 meets efficacy endpoints in phase 2 trial for papulopustular rosacea

A phase 2 clinical trial evaluating Foamix Pharmaceuticals' FMX103 to treat moderate-to-severe papulopustular rosacea (PR) demonstrated statistically significant improvement compared with vehicle in the main efficacy endpoints.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page